U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 208464
Company: GILEAD SCIENCES INC
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
VEMLIDY TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE TABLET;ORAL Prescription AB Yes Yes
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
11/10/2016 ORIG-1 Approval Type 5 - New Formulation or New Manufacturer STANDARD Label (PDF)
Letter (PDF)
Review
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208464s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208464Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208464Orig1s000TOC.cfm
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
03/27/2024 SUPPL-17 Efficacy-Labeling Change With Clinical Data Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208464s016s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208464Orig1s016,s017ltr.pdf
03/27/2024 SUPPL-16 Efficacy-New Patient Population Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208464s016s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208464Orig1s016,s017ltr.pdf
12/14/2022 SUPPL-15 Manufacturing (CMC)-Facility Letter (PDF)

Label is not available on this site.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208464Orig1s015Corrected_ltr.pdf
10/17/2022 SUPPL-14 Efficacy-New Patient Population Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208464s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/208464Orig1s014ltr.pdf
09/15/2021 SUPPL-13 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208464s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208464Orig1s013ltr.pdf
03/04/2021 SUPPL-12 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208464s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208464Orig1s012ltr.pdf
08/18/2020 SUPPL-11 Efficacy-Labeling Change With Clinical Data Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s010s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208464Orig1s010,s011ltr.pdf
08/18/2020 SUPPL-10 Efficacy-Labeling Change With Clinical Data Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s010s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208464Orig1s010,s011ltr.pdf
02/04/2020 SUPPL-8 Efficacy-Labeling Change With Clinical Data Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208464Orig1s008ltr.pdf
02/04/2019 SUPPL-7 Efficacy-New Patient Population Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208464s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208464Orig1s007ltr.pdf
07/03/2018 SUPPL-4 Efficacy-Labeling Change With Clinical Data Letter (PDF)

Label is not available on this site.

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208464Orig1s004ltr.pdf
04/07/2017 SUPPL-1 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208464s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208464Orig1s001ltr.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
03/27/2024 SUPPL-17 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208464s016s017lbl.pdf
03/27/2024 SUPPL-16 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208464s016s017lbl.pdf
10/17/2022 SUPPL-14 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208464s014lbl.pdf
09/15/2021 SUPPL-13 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208464s013lbl.pdf
03/04/2021 SUPPL-12 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208464s012lbl.pdf
08/18/2020 SUPPL-11 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s010s011lbl.pdf
08/18/2020 SUPPL-10 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s010s011lbl.pdf
02/04/2020 SUPPL-8 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf
02/04/2019 SUPPL-7 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208464s007lbl.pdf
04/07/2017 SUPPL-1 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208464s001lbl.pdf
11/10/2016 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208464s000lbl.pdf

VEMLIDY

TABLET;ORAL; EQ 25MG BASE
TE Code = AB

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
TENOFOVIR ALAFENAMIDE TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE TABLET;ORAL Prescription No AB 214226 LUPIN LTD
VEMLIDY TENOFOVIR ALAFENAMIDE FUMARATE EQ 25MG BASE TABLET;ORAL Prescription Yes AB 208464 GILEAD SCIENCES INC
Back to Top